<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580294</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 07-0464</org_study_id>
    <nct_id>NCT00580294</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)</brief_title>
  <official_title>A Pilot Study of Rapid Opioid Rotation and Titration of Oxymorphone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if changing from one pain medication like morphine or
      oxycodone to another pain medication, oxymorphone (OPANAÂ®), will be helpful to patients. This
      study will examine if the switching from one pain medication to another can be done over a 24
      hour period. Oxymorphone, the drug being studied, is an FDA approved drug for treatment of
      severe pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Patient Global Impression of Change</measure>
    <time_frame>baseline and 12 hours</time_frame>
    <description>PGIC score - participants answered 2 questions regarding change in overall status and overall activity from baseline using a 7-point scale (1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, 7 = Very Much Worse)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>Assessed daily for 10 days prior to IV PCA treatment, and assessed daily for 2 weeks after IV PCA treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>oxymorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymorphone</intervention_name>
    <description>IV PO</description>
    <arm_group_label>oxymorphone</arm_group_label>
    <other_name>Oxymorphone PO</other_name>
    <other_name>Oxymorphone IV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 to no upper limit

          -  Chronic pain of nociceptive, neuropathic, or mixed origin

          -  Patients with chronic non cancer pain

          -  Ongoing chronic opioid treatment with either oral morphine or oxycodone (long term -
             more than 3 months of at least a total daily opioid dose of 60 mg morphine or of 30 mg
             oxycodone)

          -  Pain of moderate intensity (&gt;4, on the numerical scale 0-10) despite ongoing opioid
             therapy&gt;

          -  Non-pregnant, non-lactating women

          -  Sufficient language skills to communicate with research staff

        Exclusion Criteria:Non-ambulatory patients

          -  Clinically significant respiratory, renal, hepatic, or cardiac disease.

          -  Documented diagnosis of sleep apnea (the study physician may exclude patients who
             present with clinical features and complaints suggestive of a diagnosis of probable
             sleep apnea)

          -  History of illicit drug or alcohol dependence or abuse, abnormal drug taking / seeking
             behaviors

          -  Severe depression (&gt; 26 on the BDI)

          -  Patients who exhibit a score on the Mini Mental Status Exam (MMSE) of 26 or less. (The
             range of scores for mild dementia is 21-26 on the MMSE).

          -  Workman compensation, current or pending medical-legal litigation

          -  Hypersensitivity to study medication (oxymorphone)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Pappagallo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medcine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medcine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Korkmazsky M, Ghandehari J, Sanchez A, Lin HM, Pappagallo M. Feasibility study of rapid opioid rotation and titration. Pain Physician. 2011 Jan-Feb;14(1):71-82. Erratum in: Pain Physician. 2011 Mar-Apr;14(2):217. Lin, Huong-Mo [corrected to Lin, Hung-Mo].</citation>
    <PMID>21267044</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>November 25, 2015</results_first_submitted>
  <results_first_submitted_qc>January 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sciatica</keyword>
  <keyword>Diabetic Neuropathies</keyword>
  <keyword>Complex Regional Pain Syndromes</keyword>
  <keyword>Low Back Pain</keyword>
  <keyword>Neck Pain</keyword>
  <keyword>Headache</keyword>
  <keyword>Back Pain</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Brachial Plexus Injury (stinger/burner)</keyword>
  <keyword>Chronic Pain</keyword>
  <keyword>Contractures</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Fibromyalgia</keyword>
  <keyword>Foot Pain</keyword>
  <keyword>Fracture</keyword>
  <keyword>Hip</keyword>
  <keyword>Herpes Zoster (shingles)</keyword>
  <keyword>Migraine</keyword>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Scoliosis</keyword>
  <keyword>Nerve pain</keyword>
  <keyword>Opana</keyword>
  <keyword>Opioid</keyword>
  <keyword>Opioid Rotation</keyword>
  <keyword>Oxymorphone</keyword>
  <keyword>Morphine</keyword>
  <keyword>neuropathic</keyword>
  <keyword>oxycodone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Oxymorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>study conducted at Mount Sinai School of Medicine, Department of Anesthesiology, Clinical Research Center (CRC), New York, NY, and enrolled patients from August 10, 2007 to August 9, 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxymorphone</title>
          <description>participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxymorphone</title>
          <description>oral oxymorphone ER as the basal opioid during the first 24 hours and supplemental IV-PCA oxymorphone as needed during period 1. During period 2, participants underwent a 2-week oral titration. The oxymorphone ER and IR dosages were adjusted up or down as needed to maintain pain control.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Pain Intensity</title>
          <description>Brief Pain Inventory average daily pain (0= no pain, 10=worst imaginable pain)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.34" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Patient Global Impression of Change</title>
        <description>PGIC score - participants answered 2 questions regarding change in overall status and overall activity from baseline using a 7-point scale (1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, 7 = Very Much Worse)</description>
        <time_frame>baseline and 12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxymorphone</title>
            <description>oral oxymorphone ER as the basal opioid during the first 24 hours and supplemental IV-PCA oxymorphone as needed during period 1. During period 2, participants underwent a 2-week oral titration. The oxymorphone ER and IR dosages were adjusted up or down as needed to maintain pain control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Global Impression of Change</title>
          <description>PGIC score - participants answered 2 questions regarding change in overall status and overall activity from baseline using a 7-point scale (1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, 7 = Very Much Worse)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.08" upper_limit="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brief Pain Inventory</title>
        <time_frame>Assessed daily for 10 days prior to IV PCA treatment, and assessed daily for 2 weeks after IV PCA treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oxymorphone</title>
          <description>oral oxymorphone ER as the basal opioid during the first 24 hours and supplemental IV-PCA oxymorphone as needed during period 1. During period 2, participants underwent a 2-week oral titration. The oxymorphone ER and IR dosages were adjusted up or down as needed to maintain pain control.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a pilot open-label study in a small number of participants. A larger randomized study with long-term follow-up and comparison to traditional protocols is necessary to affirm safety. (12 pts had 6 different chronic non-cancer pain diagnoses.)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Marco Pappagallo, MD</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-7749</phone>
      <email>dionne.bobb@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

